- In December 2024, Nyxoah SA launched its Genio neurostimulator for the treatment of obstructive sleep apnea (OSA) in England. This battery-free hypoglossal neuromodulation system, inserted via an incision and controlled by a wearable device, is now available under the NHS Specialised Services Devices Programme. The first successful implants were carried out at University College London Hospitals. Nyxoah is also seeking FDA approval in the U.S. following promising results from the DREAM IDE pivotal study
- In May 2023, Abbott received FDA approval for its spinal cord stimulation (SCS) systems, designed to treat chronic back pain in individuals who are either ineligible for or have not had back surgery, known as non-surgical back pain. This new approval applies to all of Abbott's SCS products in the U.S., including the Eterna SCS platform and the Proclaim SCS family
- In April 2023, Neuspera Medical announced that the U.S. FDA had approved its next-generation Neuspera ultra-miniaturized system, which delivers neurostimulation therapy through a wireless platform. This ultra-small system aids physicians in diagnosing deeper anatomy and offers patients an improved experience
- In January 2023, Axonics, Inc. announced the FDA approval of the Axonics R20 neurostimulator, an upgraded version of its R15 model, designed to treat chronic conditions such as overactive bladder. The R20 version boasts an operational life of at least 20 years
- In June 2021, Oticon Medical, a key player in the market, revealed that the U.S. FDA had granted premarket approval for its Neuro Cochlear Implant System. The system is intended to treat individuals 18 years or older with bilateral severe-to-profound sensorineural hearing loss
